Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
